Publication Name	World Journal of Gastroenterology
Manuscript ID	91105
Country	United States

Received	2023-12-23 03:00
Peer-Review Started	2023-12-23 03:00
To Make the First Decision
Return for Revision	2024-01-13 07:52
Revised	2024-01-22 14:19
Second Decision	2024-02-21 02:45
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2024-02-21 05:49
Articles in Press	2024-02-21 05:49
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2024-03-04 09:21
Publish the Manuscript Online	2024-03-14 17:31

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Editorial
Article Title	Vonoprazan-amoxicillin dual regimen with Saccharomyces boulardii as a rescue therapy for Helicobacter pylori: Current perspectives and implications
Manuscript Source	Invited Manuscript
All Author List	Valerie Josephine Dirjayanto, Jessica Audrey and Daniel Martin Simadibrata
Funding Agency and Grant Number
Corresponding Author	Daniel Martin Simadibrata, MD, MSc, Postdoctoral Fellow, Division of Gastroenterology and Hepatology, Mayo Clinic, 200 First St. SW, Rochester, Minnesota 55905, United States. simadibrata.daniel@mayo.edu
Key Words	Vonoprazan; Saccharomyces boulardii; Helicobacter pylori; Rescue therapy; Eradication rate
Core Tip	Vonoprazan-amoxicillin dual therapy with Saccharomyces boulardii (S. boulardii, VAS regimen) emerges as a novel rescue therapy for eradicating Helicobacter pylori (H. pylori). Vonoprazan, a potassium-competitive acid blocker, exhibits superior acid suppression compared to proton pump inhibitors. Notably, dual therapy minimizes the use of an additional antibiotic while maintaining efficacy comparable to traditional triple therapy. This paper highlights the role of S. boulardii, a probiotic, in enhancing the efficacy of Vonoprazan dual therapy by restoring gut microbiota balance, directly affecting H. pylori, and regulating immunomodulation. The VAS regimen emerges as a promising treatment alternative, demonstrating remarkable eradication of H. pylori, even in triple-resistant strains.
Publish Date	2024-03-14 17:31
Citation	Dirjayanto VJ, Audrey J, Simadibrata DM. Vonoprazan-amoxicillin dual regimen with Saccharomyces boulardii as a rescue therapy for Helicobacter pylori: Current perspectives and implications. World J Gastroenterol 2024; 30(10): 1280-1286
URL	https://www.wjgnet.com/1007-9327/full/v30/i10/1280.htm
DOI	https://dx.doi.org/10.3748/wjg.v30.i10.1280

Full Article (PDF)	WJG-30-1280-with-cover.pdf
Full Article (Word)	WJG-30-1280.docx
Manuscript File	91105_Auto_Edited-YJP.docx
Answering Reviewers	91105-Answering reviewers.pdf
Audio Core Tip	91105-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	91105-Conflict-of-interest statement.pdf
Copyright License Agreement	91105-Copyright license agreement.pdf
Peer-review Report	91105-Peer-review(s).pdf
Scientific Misconduct Check	91105-Bing-Lin C-2.png
Scientific Editor Work List	91105-Scientific editor work list.pdf